GeoVax to present its plug and play vaccine technology at New York Academy of Sciences Vaccine Conference


Atlanta-based biotechnology company developing human vaccines, GeoVax Labs Inc has announced that it will deliver a presentation showcasing the company’s unique technology during the Innovative Vaccines Against Resistant Infectious Diseases and Emerging Threats Conference, presented by the Microbiology and Infectious Diseases Discussion Group of The New York Academy of Sciences.


The conference is being held May 20, 2019 in New York, New York. GeoVax’s presentation is entitled “Development of Single-Dose Vaccines for Emerging Infectious Diseases Using a Novel Plug and Play Live Viral Vector Platform, Preclinical Data for Zika, Ebola and Lassa Fever Vaccines as Examples.”


The poster presentation will be delivered by Michael Hellerstein, GeoVax’s Director of Regulatory Affairs and Quality Systems, and will feature GeoVax’s “Plug and Play” vaccine platform which utilizes its recombinant Modified Vaccinia Ankara (MVA) vector to express foreign antigens on virus-like particles (VLPs) in the person being vaccinated.


According to the company, the MVA-VLP platform has several advantages including the ability to use single inoculations to achieve full protection. Single-dose protection is a favorable characteristic of a vaccine for emerging infectious disease outbreak response, given the speed of spread of pathogens and the impracticality of multi-dose regimens in the under-resourced settings where outbreaks often occurs. In studies for Ebola, Lassa and Zika, representing important human pathogens from 3 different virus families, a single dose of GeoVax’s vaccine fully protected animals against a lethal challenge. These serve as examples of the broad utility of the MVA-VLP platform for many more indications. GeoVax’s MVA platform has previously been shown to elicit both durable antibody and T cell responses against HIV in several clinical trials.


Commenting on the upcoming presentation, Farshad Guirakhoo, Ph.D., GeoVax Chief Scientific Officer stated, “GeoVax’s MVA-VLP platform technology is built upon a 5th generation MVA vector system that is improved for balanced and stable expression of vaccine transgenes, and VLP formation, during manufacture. It has the advantages of being a live replication-competent vector in avian cells for manufacturing, yet replication-deficient in mammalian cells for vaccination, thus inherently safe. Importantly, MVA vaccines elicit protective T cell as well as antibody responses in animals and humans. The MVA platform can be combined with the potent immunogenicity of VLPs or be used to express proteins in their native multimeric conformations enabling vaccines that induce full protection after a single dose. The safety and immunogenicity of the platform was first validated in animal and human studies using DNA and MVA-VLP-HIV vaccines and further expanded for developing vaccines against emerging pathogens, endemic diseases, chronic infections and cancer. Moving forward we look forward to clinical validation of our technology in multiple indications, including infectious diseases, immuno-oncology and immunotherapy.”

The poster presentation will feature GeoVax’s Plug and Play vaccine platform which utilizes its recombinant Modified Vaccinia Ankara (MVA) vector to express foreign antigens on virus-like particles (VLPs) in the person being vaccinated.

Recommended News